Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers

Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers

The objective of this study is to test the efficacy of low-dose aspirin (160 mg/day), given bedtime and started early during pregnancy (≤ 15 +6 weeks of gestation) in nulliparous pregnant women selected as "high-risk" by the presence of a bilateral uterine artery notch and/or bilateral uterine artery PI ≥ 1.7 during the first trimester ultrasound scan (11-13+6 weeks), to prevent the occurrence of pre-eclampsia or small for gestational age at birth.

Inclusion Criteria:

• Age ≥ 18 years
• Nulliparous (no previous pregnancy ≥ 22 SA)
• Singleton pregnancy
• Gestational age ≤ 15 +6 weeks
• Bilateral uterine artery notch (grade ≥ 2) and/or bilateral uterine artery PI ≥ 1.7 during first trimester ultrasound (CRL between 45 and 84 mm)
• Maternal informed consent obtained
• Affiliated to social security system

Exclusion Criteria:

• Women considering voluntary pregnancy termination (≤ 14 weeks)
• Pre-existing (maternal) indication for premature delivery before 37 weeks
• Fetal condition detected during the first trimester scan (fetal malformation or nuchal translucency ≥ 95th percentile)
• Women under anticoagulation
• Allergy or hypersensitivity to Kardegic® or one of its constituents
• Secondary hemostasis disorder responsible for bleeding or risk of bleeding
• Peptic ulcer under evolution
• Lupus or antiphospholipid syndrome